An investor could consider taking a look at the Sorrento Therapeutics (NASDAQ:SRNE) stock this morning, considering the fact that it has managed to clock gains of 12% over the course of the past week.
The company and its collaborators recently made progress with regards to the use of fully human monoclonal antibodies meant for the treatment of COVID 19 and cancer. However, that is not all.
The company was also awarded the much-needed approval from the United States Food and Drug Administration to commence its Phase 2 clinical study into its product STI 3031 for treatment of patients suffering from urothelial carcinoma. These are some of the important milestones that might have led to the wave of optimism around the Sorrento Therapeutics stock in recent times. Last but not the least, last month the company had also reached an agreement with regards to the acquisition of the oncology firm ACEA Therapeutics.